CN114886895B - Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B - Google Patents
Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B Download PDFInfo
- Publication number
- CN114886895B CN114886895B CN202210576920.2A CN202210576920A CN114886895B CN 114886895 B CN114886895 B CN 114886895B CN 202210576920 A CN202210576920 A CN 202210576920A CN 114886895 B CN114886895 B CN 114886895B
- Authority
- CN
- China
- Prior art keywords
- bay87
- medicament
- hepatitis
- hbv
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CDJNNOJINJAXPV-UHFFFAOYSA-N 5-[1-[[2-(4-cyclopropylpiperazin-1-yl)pyridin-4-yl]methyl]-5-methylpyrazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole Chemical compound CC1=CC(C=2ON=C(N=2)C=2C=CC(OC(F)(F)F)=CC=2)=NN1CC(C=1)=CC=NC=1N(CC1)CCN1C1CC1 CDJNNOJINJAXPV-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 239000003112 inhibitor Substances 0.000 title claims abstract description 15
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 11
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 8
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 51
- 230000010076 replication Effects 0.000 claims abstract description 15
- 238000013518 transcription Methods 0.000 claims abstract description 12
- 230000035897 transcription Effects 0.000 claims abstract description 12
- 108091036055 CccDNA Proteins 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 48
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 101710142246 External core antigen Proteins 0.000 description 11
- 230000028327 secretion Effects 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B virus infection. The invention uses different liver cancer cell lines which can stably produce Hepatitis B Virus (HBV) or HBV-infected human primary liver cells to verify that BAY87-2243 can obviously inhibit HBV transcription and replication and effectively reduce cccDNA expression level through the in vitro treatment of BAY87-2243 with different concentrations.
Description
Technical Field
The invention relates to application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B
Background
Viral hepatitis B (viral hepatitis type B) is an infectious disease mainly caused by Hepatitis B Virus (HBV) and characterized by liver disease. Clinically, the symptoms of anorexia, nausea, epigastric discomfort, liver pain and hypodynamia are mainly manifested. Some patients may have jaundice fever and hepatomegaly with impaired liver function. Some patients can become chronic, even develop cirrhosis of the liver, and a few can develop liver cancer.
At present, the effect of treating chronic HBV infection by nucleoside (acid) analogues and interferon is very limited, and only a few patients can realize 'functional cure'. The key to cure chronic hepatitis B virus infection is that covalently closed circular DNA (cccDNA) in host hepatocytes must be thoroughly eliminated, and the cccDNA is a template for HBV transcription replication and a viral gene repository and is also a key cause for relapse after drug withdrawal of patients with chronic hepatitis B. At present, the medicine for effectively removing cccDNA is still lacking clinically, so the search and development of the medicine for effectively removing the hepatitis B virus cccDNA have good clinical application prospects.
The small molecule inhibitor BAY87-2243 is a potent selective hypoxia-inhibitor factor-1 (HIF-1) inhibitor. At present, research reports show that the compounds can inhibit tumor cell proliferation by interfering mitochondrial function, can be used for treating cancers such as lung cancer, also report research that the compounds have positive influence on Intestinal Mucosa Barrier (IMB) function, and can be used for treating sepsis. No BAY87-2243 is reported to be used for treating hepatitis B at present.
Disclosure of Invention
In order to solve the problems, the invention provides the application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B; the BAY87-2243 is a HIF-1 specific inhibitor.
Further, the drug is a drug that reduces the level of hepatitis b surface antigen production.
Further, the drug is a drug that reduces the level of hepatitis b e antigen production.
Further, the drug is a drug that inhibits transcription of hepatitis b virus.
Further, the medicament is a medicament for inhibiting the replication of hepatitis B virus DNA.
Further, the medicament is a medicament that reduces the expression level of hepatitis b virus cccDNA.
Furthermore, the medicine is a preparation prepared by taking a small molecular inhibitor BAY87-2243 as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
Still further, the formulation is an oral formulation; the oral preparation is granule, solution, pill, paste or tablet.
Experiments prove that the small molecular inhibitor BAY87-2243 can obviously inhibit HBV transcription and replication and effectively reduce the cccDNA expression level, so that the complete elimination of the virus carrying state of a hepatitis B patient becomes possible, the aim of antiviral treatment is finally achieved, and the application has practical popularization and application prospects.
It will be apparent that various other modifications, substitutions and alterations can be made in the present invention without departing from the basic technical concept of the invention as described above, according to the common technical knowledge and common practice in the field.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 statistical data of the study on HBsAg/HBeAg secretion by BAY87-2243 treatment (A: effect of different concentrations of BAY87-2243 treatment on HepAD38 cytotoxicity and HBsAg secretion, B: effect of different concentrations of BAY87-2243 treatment on HepG2.2.15 cytotoxicity and HBsAg secretion, C: effect of different concentrations of BAY87-2243 treatment on HepAD38 cytotoxicity and HBeAg secretion, D: effect of different concentrations of BAY87-2243 treatment on HepG2.2.15 cytotoxicity and HBeAg secretion)
FIG. 2 statistical data of the effects of BAY87-2243 treatment on HBV transcription and replication levels and HBV cccDNA expression levels (A: the effect of BAY87-2243 treatment on HBV total RNA expression level in HepAD38 cells, B: the effect of BAY87-2243 treatment on HBVpgRNA expression level in HepAD38 cells, C: the effect of BAY87-2243 treatment on HBVDNA replication level in HepAD38 cells, D: the effect of BAY87-2243 treatment on HBVccc DNA expression level in HepAD38 cells) FIG. 3 in HBV-infected human primary hepatocytes, statistical data of the effects of BAY87-2243 treatment on HBV transcription and HBV replication levels and HBV cccDNA expression level (A: the effect of BAY87-2243 treatment on HBsAg secretion level, B: the effect of BAY87-2243 treatment on HBeAg secretion level, C: the effect of BAY87-2243 treatment on HBV total RNA expression level, B: the effect of BAY87-2243 treatment on HBgRNA expression level in HBeAg, and VpeAg expression level of HBgRNA in HBeAg
Detailed Description
Example 1 Effect of BAY87-2243 on secretion of HBsAg/HBeAg in hepatoma cells stably producing HBV
First, 8 × 10 4 One/well hepg2.215 and HepAD38 cells were seeded in 48-well plates, respectively. The next day after cell plating, cells were treated with different concentration gradients (0.01-100 nM) of BAY87-2243, respectively. After BAY87 treated the cells for 72h, cell Counting Kit-8 reagent (MedChemexpress, HY-K0301) was added to the 48-well plate, and the change in absorbance of the cells was detected by a multifunctional microplate reader at a wavelength of 450 nm. In addition, the cell supernatant was collected and the levels of HBsAg and HBeAg secreted in the cell supernatant were detected using a hepatitis B virus surface antigen diagnostic kit (enzyme-linked immunosorbent assay; shanghai Kehua, SI 0910113) and a hepatitis B virus E antigen detection kit (enzyme-linked immunosorbent assay; shanghai Kehua, 20163400144), respectively. The specific results of the microplate reader and the ELISA kit are shown in FIGS. 1A-D. From the results of the figures, it can be seen that: BAY87-2243 concentrations have a lesser effect on cytotoxicity at 100nM, and lower concentrations (<0.1 nM) of BAY87-2243 is effective in inhibiting secretion of HBsAg and HBeAg.
Example 2 Effect of BAY87-2243 on HBV transcription and replication levels and HBV cccDNA expression levels in HepAD38 cells
Will be 3X 10 5 One/well HepAD38 cells were seeded in 12-well plates, treated the next day with BAY87 at different concentration gradients (1, 2 or 4 nM) for 72h, then total intracellular RNA was extracted using Trizol reagent (Invitrogen, 15596026), and One-Step real RT-qPCR kit [ One Step TB
PrimeScript TM RT-PCR Kit II(Perfect Real Time)，TaKaRa，RR086]Expression levels of HBV total RNA (FIG. 2A) and pgRNA (FIG. 2B) were measured in cells. From the results of the figures, it can be seen that: BAY87-2243 treatment with different concentrations can obviously reduce the expression level of HBV total RNA and pgRNA in cells, which indicates that BAY87-2243 can effectively inhibit HBV transcription in cells.
Will be 6X 10 5 The HepAD38 cells per well are inoculated in a 6-well plate, the next day, the cells are treated for 72h by BAY87-2243 with different concentration gradients (1, 2 or 4 nM), the cells are lysed, HBV DNA wrapped by nucleocapsid in the cells is extracted, and the influence of BAY87-2243 on the replication level of the HBV DNA in the cells is detected by a Southern blot method. The specific results are shown in FIG. 2C. From the graph results, it can be seen that: treatment with BAY87-2243 with different concentrations can obviously reduce the replication level of HBV DNA in cells, and the suggestion that BAY87-2243 can effectively inhibit the replication of HBV DNA in cells.
Will be 6X 10 5 HepAD38 cells were seeded in 6-well plates and treated the following day with varying concentration gradients (1, 2 or 4 nM) of BAY87-2243 for 96h. Then washing the cells with PBS 2 times, lysing the cells overnight, extracting DNA with phenol chloroform, subjecting the cccDNA obtained to an enzymatic cleavage reaction with T5 exonuclease, and performing Realtime qPCR (polymerase chain reaction)
Probe qPCR Master Mix, promega, a 6101) to detect HBV cccDNA expression levels in cells. The specific results are shown in FIG. 2D. From the graph results, it can be seen that: treatment of BAY87-2243 with different concentrations can obviously reduce the expression level of HBV cccDNA in cells, and the fact that BAY87-2243 can effectively reduce the expression level of HBVcccDNA in cells is suggested.
Example 3 investigation of the Effect of BAY87-2243 on HBV transcription and replication levels and HBV cccDNA expression levels in HBV-infected human primary hepatocytes
Commercial human primary cells were expanded at 5X 10 5 One/well was seeded in 12-well plates, and the next day after cell plating, cells were incubated with William's E complete medium containing HBV viral particles (MOI: 1000); 24h after HBV infection, cells were washed 3 times with PBS and then treated with BAY87-2243 at different concentration gradients (2 nM and 4 nM) for 6 consecutive days. Collecting cell supernatant, using (hepatitis B virus surface antigen diagnostic kit (enzyme linked immunosorbent assay) and hepatitis B virus E antigen detection kit (enzyme linked immunosorbent assay) to respectively collect cell supernatant and then detect the level of HBsAg and HBeAg secreted in the cell supernatant, and the specific results are shown in figures 3A-B, and the results of the figures show that BAY87-2243 can effectively inhibit the secretion of HBsAg and HBeAg.
Cells treated as in FIGS. 3A-B were washed 2 times with PBS, total RNA in the cells was extracted using Trizol reagent, and expression levels of HBV total RNA (FIG. 3C) and pgRNA (FIG. 3D) in the cells were measured using One-step simple RT-qPCR kit. From the results of the figures, it can be seen that: BAY87-2243 with different concentrations can obviously reduce the expression level of HBV total RNA and pgRNA in hepatocytes, which indicates that BAY87-2243 can effectively inhibit HBV transcription in primary human hepatocytes.
Cells treated as in FIGS. 3A-B were washed 2 times with PBS, lysed and nucleocapsid-encapsulated HBV DNA extracted from cells with phenol-chloroform and subjected to Realtime qPCR (TB)
Premix Ex Taq TM II (Tli RNaseH Plus), taKaRa, RR 820) test the effect of BAY87-2243 on the expression level of HBV DNA in cells. The specific results are shown in FIG. 3E. From the graph results, it can be seen that: BAY87-2243 treatment can obviously reduce the expression level of HBV DNA in cells, and the suggestion that BAY87-2243 can effectively inhibit the replication of HBVDNA in primary human hepatocytes.
The cells treated as in FIGS. 3A-B were washed 2 times with PBS, lysed and then the DNA was extracted with phenol chloroform, and finally the cccDNA obtained was cleaved with T5 exonuclease and processed with Realtime qPCR (R) (C)
Probe qPCR Master Mix, promega, a 6101) to detect HBV cccDNA expression levels in cells. The specific results are shown in FIG. 3F. From the graph results, it can be seen that: BAY87-2243 treatment can obviously reduce the expression level of HBV cccDNA in cells, and suggests that BAY87-2243 can effectively reduce the expression level of HBV cccDNA in human primary hepatocytes.
In conclusion, a series of experiments prove that the small molecular inhibitor BAY87-2243 can obviously inhibit HBV transcription and replication, effectively reduce cccDNA expression level, enable complete elimination of the virus carrying state of a hepatitis B patient to be possible, finally realize the aim of antiviral therapy, and has practical popularization and application prospects.
Claims (9)
1. The use of small molecule inhibitor BAY87-2243 in the preparation of medicine for treating hepatitis B; the BAY87-2243 is a HIF-1 specific inhibitor.
2. The use according to claim 1, wherein the medicament is a medicament for reducing the level of hepatitis b surface antigen production.
3. The use of claim 1, wherein the medicament is a medicament that reduces the level of hepatitis b e antigen production.
4. The use according to claim 1, wherein the medicament is a medicament for inhibiting transcription of hepatitis b virus.
5. The use according to claim 1, wherein the medicament is a medicament for inhibiting replication of hepatitis b virus DNA.
6. The use of claim 1, wherein the medicament is a medicament that reduces the expression level of hepatitis b virus cccDNA.
7. The use according to any one of claims 1 to 6, characterized in that the medicament is a preparation prepared by taking a small molecule inhibitor BAY87-2243 as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
8. Use according to claim 7, wherein the formulation is an oral formulation.
9. Use according to claim 8, characterized in that the oral formulation is a granule, solution, pill, paste or tablet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022105292369 | 2022-05-16 | ||
| CN202210529236 | 2022-05-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114886895A CN114886895A (en) | 2022-08-12 |
| CN114886895B true CN114886895B (en) | 2023-02-03 |
Family
ID=82726225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210576920.2A Active CN114886895B (en) | 2022-05-16 | 2022-05-25 | Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114886895B (en) |
| WO (1) | WO2023221361A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114886895B (en) * | 2022-05-16 | 2023-02-03 | 重庆医科大学 | Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022093770A1 (en) * | 2020-10-27 | 2022-05-05 | Memorial Sloan Kettering Cancer Center | Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381463A (en) * | 2017-08-08 | 2019-02-26 | 复旦大学 | Application of the tazarotene in preparation treatment hepatitis B virus infection drug |
| US11555191B2 (en) * | 2017-09-01 | 2023-01-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitor for use for preventing and/or treating an infection with hepatitis B virus |
| CN113337602A (en) * | 2020-03-02 | 2021-09-03 | 苏州亚盛药业有限公司 | Methods of treatment and biomarkers for MDM2 inhibitors |
| CN114886895B (en) * | 2022-05-16 | 2023-02-03 | 重庆医科大学 | Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B |
-
2022
- 2022-05-25 CN CN202210576920.2A patent/CN114886895B/en active Active
- 2022-09-27 WO PCT/CN2022/121759 patent/WO2023221361A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022093770A1 (en) * | 2020-10-27 | 2022-05-05 | Memorial Sloan Kettering Cancer Center | Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114886895A (en) | 2022-08-12 |
| WO2023221361A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114886895B (en) | Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B | |
| Ali et al. | Synthesis of avian oncornavirus DNA in infected chicken cells | |
| EA036745B1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| CN103458913A (en) | Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases | |
| CN109364074B (en) | Application of 6-aminonicotinamide as effective component in preparing medicament for treating hepatitis B | |
| CN114073699A (en) | Use of rapamycin for treating or preventing hepatitis B | |
| CN114159572B (en) | A pharmaceutical composition for the treatment of viral hepatitis | |
| CN114832023A (en) | Application of effective component of Geranium wilfordii for treating or preventing viral hepatitis | |
| CN102631384B (en) | Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection | |
| Furusawa et al. | Therapeutic activity of pretazettine on Rauscher leukemia: combination of antiviral activity and cellular protein inhibition | |
| CN102337263B (en) | siRNA (Small interfering ribonucleic acid) capable of inhibiting expression of enterovirus 71 type gene, composition and application | |
| CN114246847B (en) | Application of chalcone compounds in treatment of coronavirus infection | |
| CN114209844B (en) | A pharmaceutical composition for treating viral hepatitis | |
| CN115105519A (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| EP0643970A2 (en) | 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans | |
| Rizzeto et al. | The hepatitis delta virus and its infection | |
| CN113304165B (en) | Application of monomeric compound Ciliaoside A in preparation of hepatitis B treatment drug | |
| Yu et al. | Strongylocentrotus nudus egg polysaccharide (SEP) suppresses HBV replication via activation of TLR4-induced immune pathway | |
| CN105031613B (en) | A kind of human beta-defensin 1 is preparing the application in treating or preventing hepatitis B virus infective medicament | |
| CN115887452A (en) | Use of rapamycin for treating or preventing hepatitis B | |
| CN113502288A (en) | Antisense oligonucleotide and application thereof in inhibiting new coronavirus | |
| CN109811030B (en) | Application of antazoline hydrochloride derivative as HBV inhibitor | |
| CN114515338B (en) | Pharmaceutical composition for treating viral hepatitis | |
| CN117281800A (en) | Application of niclosamide in preparing medicine for treating hepatitis B | |
| CN113975267B (en) | Application of 6 alpha-hydroxyeyeurycommactone in preparation of anti-dengue virus drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |